Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Revvity Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $2.16, while Revvity Inc trades at $110.1 (market cap $11.87B). The key difference: Revvity Inc pays a 0.26% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Revvity Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | RVTY | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $92.70 | $117.75 |
52-Week Low | $1.46 | $82.26 |
Market Cap | — | $11.87B |
Enterprise Value | — | $14.36B |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU is trading at $1.98, up 6.45% today, but faces significant headwinds with a bearish technical outlook and concerning fundamental metrics. The leveraged ETF structure has resulted in substantial losses, with reports indicating a 98% decline from November 2024 levels. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while key financial ratios remain unavailable for analysis.
The outlook remains challenging due to the ETF's leveraged structure and volatility decay. Investment opportunities are limited given the historical performance, while risks include continued erosion of value from daily rebalancing and dependence on MicroStrategy's underlying performance. The fund's viability remains in question based on recent performance trends.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
